ProCE Banner Activity

Biomarker Testing and Novel Targeted Agents in the Management of Gastrointestinal Cancers: Experts Address FAQs

Clinical Thought
In this commentary, experts answer audience questions from a live satellite symposium presented at ASCO 2022 on the role of biomarker testing in gastrointestinal cancers and review novel targeted agents and approaches for patients with metastatic disease.

Released: August 22, 2022

Expiration: August 21, 2023

No longer available for credit.

Share

Faculty

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Michael J. Pishvaian

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Manish A. Shah

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Seagen Inc.

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD: consultant/advisor/speaker: Bayer, Merck, Pfizer, Taiho, Caris; salary: Indivumed.

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Michael J. Pishvaian, MD, PhD: consultant/advisor/speaker: AstraZeneca, Merck, Novartis, Pfizer; researcher: Arcus Bio, Ideaya, Merck, Novartis, Pfizer, Repare Tx, Seattle Genetics, Takeda, Tesaro, Tizonia; ownership/intellectual property: AbbVie, Perthera.

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Manish A. Shah, MD: researcher: Bristol-Myers Squibb, Merck.